Insight
Botensilimab
Photo taken from Agenus/LinkedIn

Breelyn Wilky on botensilimab and balstilimab for refractory sarcomas at ESMO24

Agenus shared on LinkedIn:

“Breelyn Wilky, presented new data at ESMO24 highlighting the potential of our investigational immunotherapy combination, botensilimab and balstilimab, for treating patients with refractory sarcomas.

Learn more about this advancement.”

Source: Agenus/LinkedIn

Agenus Balstilimab botensilimab Breelyn Wilky cancer ESMO ESMO24 immunotherapy OncoDaily Oncology refractory sarcomas sarcomas